Recent regulatory filings reveal that RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah have liquidated a significant portion of their holdings in Werewolf Therapeutics, Inc. (NASDAQ: HOWL). The transactions, totaling roughly $390,688 in common stock, were carried out between May 8 and May 12, 2026.
The sales were executed indirectly through two managed entities: RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P. Both funds fall under the management of RA Capital Management, L.P. Furthermore, Peter Kolchinsky and Rajeev Shah serve as managing members of the general partner for RA Capital Management, L.P., linking them to these transactions. All three reporting parties are classified as ten percent owners of the biotech company.
Breakdown of Transaction Activity
The liquidation occurred in three distinct phases throughout the reported week:
- May 8, 2026: A total of 376,526 shares were sold at a weighted average price of $0.71 per share. Individual transaction prices during this period ranged from a low of $0.69 to a high of $0.76. Within this volume, RA Capital Healthcare Fund, L.P. sold 351,514 shares for approximately $249,575, while RA Capital Nexus Fund II, L.P. disposed of 25,012 shares totaling about $17,759.
- May 11, 2026: The second wave involved the sale of 87,490 shares at a weighted average price of $0.67 per share. Prices for these trades fluctuated between $0.66 and $0.71. RA Capital Healthcare Fund, L.P. accounted for 81,678 shares sold (approximately $54,724), while RA Capital Nexus Fund II, L.P. sold 5,812 shares (approximately $3,894).
- May 12, 2026: The final recorded transactions included 101,151 shares sold at a weighted average price of $0.64 per share, with prices ranging from $0.62 to $0.65. RA Capital Healthcare Fund, L.P. sold 94,432 shares for roughly $60,436, and RA Capital Nexus Fund II, L.P. sold 6,719 shares for approximately $4,300.
Following these movements, the remaining holdings for the funds consist of 5,709,858 shares held by RA Capital Healthcare Fund, L.P. and 406,282 shares held by RA Capital Nexus Fund II, L.P. The reporting parties disclaim beneficial ownership except to the extent of their own pecuniary interest.
Operational Context and Strategic Shifts
These insider sales coincide with a period of intense structural change for Werewolf Therapeutics. The company has officially announced that it is exploring various strategic alternatives intended to enhance value for its stockholders. To facilitate this evaluation, the firm has engaged Piper Sandler & Co. as an exclusive financial advisor. The potential pathways under consideration include:
- Mergers or business combinations
- Asset sales or a complete sale of the company
- Licensing agreements or collaborative arrangements
In tandem with these strategic explorations, Werewolf Therapeutics has moved to drastically reduce its operating expenses through a significant workforce reduction. The board of directors approved a plan to cut 64% of the company's total employees, a process that is expected to be largely finished by February 13, 2026.
Financial Standing and Market Position
As of the first quarter of 2026, the company’s financial profile shows it remains unprofitable, reporting earnings per share (EPS) of -$1.24 over the previous twelve months. Despite this loss, the balance sheet indicates that the firm maintains more cash than debt. The stock's current trading price of $0.63 sits just above its 52-week low of $0.53, reflecting recent market pressures on the $31.1 million market cap entity.